Prostate cancer. World Health Organization classification, 5th edition
https://doi.org/10.17650/2618-7019-2022-5-3-4-17-22
Abstract
The fifth edition of the World Health Organization classification of the urinary and male genital tumors was published in 2022. There are no major changes in the section of prostate tumors; however, they deserve attention since they are based on the amendments to the previous editions. This article analyzes the updates to the World Health Organization classification of prostate tumors.
Keywords
prostate cancer,
classification of the World Health Organization 2022,
intraductal carcinoma,
cribriform structures
Supporting agencies: The work was performed without external funding
About the Author
N. A. Gorban
Central Clinical Hospital with Polyclinic, Administration of the President of the Russian Federation; 15 Marshala Timoshenko St., Moscow 121359, Russia
Russian Federation
Russian Federation
References
1. Netto G.J., Amin M.B., Kench J.G. et al. Chapter 4: Tumours of the Prostate. In: WHO Classification of Tumours: Urinary and Male Genital Tumours. Lyon: International Agency for Research on Cancer; 2022. Available at: https://tumourclassification.iarc.who.int/chapters/36.
2. Eble J.N.S.G., Epstein J.I., Sesterhenn I.A. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.
3. Moch H.H.P., Ulbright T.M., Reuter V. The WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2016.
4. Humphery H.A. Prostate Pathology. Chicago: ASCP-Press; 2003. P. 556.
5. Kench J.G., Amin M.B., Berney D.M. et al. WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. Histopathology. 2022;81:447–458. DOI: 10.1111/his.14711.
6. Kaur H.B., Salles D.C., Paulk A. et al. PIN-like ductal carcinoma of the prostate has frequent activating RAS/RAF mutations. Histopathology. 2021;78:327–333.
7. Seipel A.H., Delahunt B., Samaratunga H. et al. Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists. Histopathology. 2014;65:216–227.
8. Epstein J.I., Netto G.J. Biopsy Interpretation of the Prostate. Lippincott Williams & Wilkins; 2008. 358 p.
9. Bostwick D.G., Cheng L. Precursors of prostate cancer. Histopathology. 2012;60(1):4–27. DOI: 10.1111/j.1365-2559.2011.04007.x.
10. Varma M., Egevad L., Algaba F. et al. Intraductal carcinoma of prostate reporting practice: a survey of expert European uropathologists. J Clin Pathol. 2016;69:852–857. DOI: 10.1136/jclinpath-2016-203658.
11. Khani F., Wobker S.E., Hicks J.L. et al. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations. J Pathol. 2019;249:79–89.
12. Kimura K., Tsuzuki T., Kato M. et al. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate. 2014;74:680–687.
13. Miyai K., Divatia M.K., Shen S.S. et al. Clinicopathological analysis of intraductal proliferative lesions of prostate: intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion. Hum Pathol. 2014;45:1572–1581.
14. Epstein J.I., Egevad L., Amin M.B. et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40:244–252.
15. Samaratunga H., Delahunt B., Egevad L. et al. Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded. Pathology. 2020;52:192–196.
16. Van Leenders G., van der Kwast T.H., Grignon D.J. et al. The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol. 2020;44:e87–e99.
17. Epstein J.I., Amin M.B., Fine S.W. et al. The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer. Arch Pathol Lab Med. 2021;145:461–493.
18. Rijstenberg L.L., Hansum T., Hollemans E. et al. Intraductal carcinoma has a minimal impact on grade group assignment in prostate cancer biopsy and radical prostatectomy specimens. Histopathology. 2020;77:742–748.
19. Hickman R.A., Yu H., Li J. et al. Atypical intraductal cribriform proliferations of the prostate exhibit similar molecular and clinicopathologic characteristics as intraductal carcinoma of the prostate. Am J Surg Pathol. 2017;41:550–556.
20. Dong F., Yang P., Wang C. et al. Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma. Am J Surg Pathol. 2013;37:1855–1861.
21. Shah R.B., Cai Q., Aron M. et al. Diagnosis of “cribriform” prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. Am J Cancer Res. 2021;11:3990–4001.
22. Egevad L., Delahunt B., Kristiansen G. et al. Contemporary prognostic indicators for prostate cancer incorporating international society of urological pathology recommendations. Pathology. 2018;50:60–73.
23. Conteduca V., Oromendia C., Eng K.W. et al. Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019;121:7–18.
24. Bishop J.A., Yonescu R., Epstein J.I., Westra W.H. A subset of prostatic basal cell carcinomas harbor the MYB rearrangement of adenoid cystic carcinoma. Hum Pathol. 2015;46:1204–1208.
25. Magers M.J., Iczkowski K.A., Montironi R. et al. MYB–NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia. Mod Pathol. 2019;32:1666–1674.
26. Simper N.B., Jones C.L., MacLennan G.T. et al. Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR. Hum Pathol. 2015;46:805–812.
27. West R.B., Kong C., Clarke N. et al. MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol. 2011;35:92–99.
Review
For citations:
Gorban N.A. Prostate cancer. World Health Organization classification, 5th edition. ONCOPATHOLOGY. 2022;5(3-4):17-22. (In Russ.) https://doi.org/10.17650/2618-7019-2022-5-3-4-17-22
Views:
16
JATS XML
Email this article 